Table 1.
Summary of key findings from the International COVID-ACS registry
| COVID-STEMI (n = 144) | Pre-COVID-19 STEMI Controls (n = 24,961) | COVID NSTE-ACS (n = 121) | Pre-COVID NSTE-ACS Controls (n = 46,389) | |
|---|---|---|---|---|
| Baseline Characteristics | ||||
| Mean age, y (SD) | 64 (13) | 66 (13) | 67 (13) | 70 (13) |
| Male | 78% | 72% | 79% | 66% |
| Hypertension | 65% | 45% | 68% | 58% |
| Hyperlipidemia | 46% | 29% | 63% | 34% |
| Diabetes mellitus | 34% | 21% | 39% | 31% |
| Chronic kidney disease | 10% | 4% | 20% | 10% |
| Symptom onset to admission, min (IQR) | 339.0 (175.0–1481.5) | 173.0 (107.0–387.0) | 417.0 (157.0–2904.0) | 295.0 (130.0–1021.0) |
| Door-to-balloon time, min (IQR) | 83.0 (37.0–336.0) | 37.0 (31.0–109.0) | - | - |
| Postprocedure | ||||
| ICU admission | 46% | NA | 34% | NA |
| Ventilation | 21% | 4% | 12% | 0.4% |
| Pressor support | 27% | 5% | 19% | 0.9% |
| Mechanical support device | 6% | 3% | 0.8% | 0.6% |
| In-hospital outcomes | ||||
| Death | 23% | 6% | 7% | 1% |
| Myocardial infarction | 6% | NA | 4% | NA |
| Stent thrombosis | 1% | NA | 0% | NA |
| Bleeding | 3% | 0.3% | 3% | 0.1% |
| Stroke | 2% | 0.1% | 0.8% | 0.1% |
| Cardiogenic shock | 20% | 9% | 5% | 1% |
| Length of hospital stay, d (IQR) | 6.5 (2.7–12.7) | 3.0 (2.0–5.0) | 6.9 (3.4–18.4) | 5.0 (3.0–8.0) |
Pre-COVID-19 STEMI controls were taken from the British Cardiovascular Intervention Society 2018 to 2019 National Audit database. Pre-COVID-19 NSTE-ACS controls were taken from the Myocardial Ischaemia National Audit Project 2019 database.
Abbreviations: IQR, interquartile range; NA, data not available; NSTE-ACS, non–ST-elevation acute coronary syndrome; SD, standard deviation; STEMI, ST-elevation myocardial infarction.
Adapted from Kite TA, Ludman PF, Gale CP, et al. International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19. J Am Coll Cardiol. 2021;77(20):2466-2476.